| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/01.ASN.0000100145.27188.33 |
| P698 | PubMed publication ID | 14638920 |
| P50 | author | Brad H Rovin | Q114447183 |
| P2093 | author name string | Sunil V Rao | |
| Lee A Hebert | |||
| William A Wilmer | |||
| Christopher J Hebert | |||
| Karen Kumor | |||
| P2860 | cites work | Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial | Q44280775 |
| P433 | issue | 12 | |
| P304 | page(s) | 3217-3232 | |
| P577 | publication date | 2003-12-01 | |
| P1433 | published in | Journal of the American Society of Nephrology | Q17123893 |
| P1476 | title | Management of glomerular proteinuria: a commentary | |
| P478 | volume | 14 |
| Q35053510 | An approach to validating criteria for proteinuric flare in systemic lupus erythematosus glomerulonephritis |
| Q37971668 | Anaplastic lymphoma kinase: activating mechanisms and signaling pathways |
| Q42871508 | Application of artificial neural networks in estimating predictive factors and therapeutic efficacy in idiopathic membranous nephropathy |
| Q89241993 | Boldine Improves Kidney Damage in the Goldblatt 2K1C Model Avoiding the Increase in TGF-β |
| Q26853664 | Cell biology and pathology of podocytes |
| Q87393398 | Chapter 12: Lupus nephritis |
| Q38035660 | Chronic renal allograft injury: early detection, accurate diagnosis and management. |
| Q47389835 | Clinical study on Yishen Qufeng Shengshi Recipe () for glomerular proteinuria patients: A randomized controlled trial |
| Q47975650 | Clinical utility of spot urine protein-to-creatinine ratio modified by estimated daily creatinine excretion in children. |
| Q34418531 | Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: a meta-analysis |
| Q55484735 | Comparative Efficacy and Safety of Therapies in IgA Nephropathy: A Network Meta-analysis of Randomized Controlled Trials. |
| Q35791773 | Comparison of estimated protein output and urine protein: creatinine ratio in first and second voids with 24-hour urine protein |
| Q43143170 | Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin II receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome |
| Q35838496 | Compelling drug indications in diabetic and nondiabetic nephropathy |
| Q53155611 | Cost-effectiveness of angiotensin-converting enzyme inhibitors in nondiabetic advanced renal disease. |
| Q36061335 | Diabetic nephropathy: the proteinuria hypothesis |
| Q38139836 | Differential diagnosis of glomerular disease: a systematic and inclusive approach |
| Q37593689 | Dual renin-angiotensin system blockade in the ONTARGET study: clinically relevant risk for the kidney? |
| Q50873297 | Effect of add-on pentoxifylline on proteinuria in membranous glomerulonephritis: a 6-month placebo-controlled trial. |
| Q41773994 | Effect of spironolactone combined with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers on chronic glomerular disease |
| Q37671099 | Effect of spironolactone on diabetic nephropathy compared to the combination of spironolactone and losartan |
| Q64128163 | Efficacy and safety of glucocorticoids for patients with IgA nephropathy: a meta-analysis |
| Q34420383 | Emerging drugs for chronic kidney disease |
| Q38042191 | Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature |
| Q36975222 | Evaluation of the effects of a therapeutic renal diet to control proteinuria in proteinuric non-azotemic dogs treated with benazepril |
| Q37992135 | Everolimus: preventing organ rejection in adult kidney transplant recipients |
| Q34149617 | FVB mouse genotype confers susceptibility to OVE26 diabetic albuminuria |
| Q37224244 | General acteoside of Rehmanniae leaves in the treatment of primary chronic glomerulonephritis: a randomized controlled trial |
| Q83786367 | Hyperphosphatemia is associated with overt proteinuria in non-diabetic patients with late-stage chronic kidney disease: a cross-sectional study |
| Q41618860 | Impaired Albumin Uptake and Processing Promote Albuminuria in OVE26 Diabetic Mice. |
| Q84120984 | Lupus nephritis: Is it time for the 12 h urine collection? |
| Q37892340 | Managing kidney disease with blood-pressure control |
| Q36654960 | Medaka fish, Oryzias latipes, as a model for human obesity-related glomerulopathy |
| Q92256415 | Minor Glomerular Abnormalities are Associated with Deterioration of Long-Term Kidney Function and Mitochondrial Injury |
| Q61974567 | Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria |
| Q35994519 | Nicorandil as a novel therapy for advanced diabetic nephropathy in the eNOS-deficient mouse |
| Q46822423 | Norcantharidin ameliorates proteinuria, associated tubulointerstitial inflammation and fibrosis in protein overload nephropathy |
| Q37940336 | Norcantharidin, a protective therapeutic agent in renal tubulointerstitial fibrosis |
| Q38260544 | Nutritional treatment in chronic kidney disease: the concept of nephroprotection. |
| Q36054872 | Optimal care of lupus nephritis patients |
| Q37415711 | Oral cyclophosphamide for lupus glomerulonephritis: an underused therapeutic option |
| Q37120467 | Peripheral edema with hypoalbuminemia in a nonhuman primate infected with simian-human immunodeficiency virus: a case report. |
| Q46468583 | Plasmapheresis for the prophylaxis and treatment of recurrent focal segmental glomerulosclerosis following renal transplant |
| Q38752824 | Primary glomerulonephritides |
| Q45275121 | Proteinuria >0.5 g/d, a prevalent prognostic factor for patient and graft survival in kidney transplantation. |
| Q33943310 | Proteinuria: an enzymatic disease of the podocyte? |
| Q37964266 | Proteinuria: detection and role in native renal disease progression |
| Q84388652 | Random spot urine protein/creatinine ratio is unreliable for estimating 24-hour proteinuria in individual systemic lupus erythematosus nephritis patients |
| Q35626485 | Random spot urine protein/creatinine ratio: a reliable method for monitoring lupus nephritis? |
| Q37629835 | Recent changes in the landscape of combination RAS blockade |
| Q57945954 | References |
| Q55470645 | Relapse or worsening of nephrotic syndrome in idiopathic membranous nephropathy can occur even though the glomerular immune deposits have been eradicated. |
| Q36736718 | Relationship between albuminuria and total proteinuria in systemic lupus erythematosus nephritis: diagnostic and therapeutic implications |
| Q36606501 | Relationship between nocturnal blood pressure and 24-h urinary sodium excretion in a rural population in Korea |
| Q51158549 | Renoprotective efficacy of valsartan in chronic non-diabetic proteinuric nephropathies with renin-angiotensin system gene polymorphisms. |
| Q81201776 | Should the target for blood pressure control specify both a systolic and a diastolic component? |
| Q46890906 | Simvastatin protection against acute immune-mediated glomerulonephritis in mice |
| Q35904809 | Slowing the progression of adult chronic kidney disease: therapeutic advances. |
| Q92457201 | Spot urine protein/creatinine ratio as a reliable estimate of 24-hour proteinuria in patients with immunoglobulin A nephropathy, but not membranous nephropathy |
| Q53620564 | Spot urine protein/creatinine ratio is unreliable estimate of 24 h proteinuria in lupus nephritis when the histological scores of activity index are higher. |
| Q35914820 | The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney Disease |
| Q53016616 | The design of ALLHAT may have biased the study's outcome in favor of the diuretic cohort. |
| Q35692435 | The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy. |
| Q37859175 | The kidney: medical nutrition therapy--yesterday and today |
| Q35573698 | The use of vitamin D analogues in chronic kidney diseases: possible mechanisms beyond bone and mineral metabolism |
| Q36510669 | Therapeutic strategies to slow chronic kidney disease progression |
| Q38094888 | Treatment of IgA nephropathy and Henoch-Schönlein nephritis |
| Q37507490 | Treatment of focal segmental glomerulosclerosis with immunophilin modulation: when did we stop thinking about pathogenesis? |
| Q36447934 | Update on immunoglobulin a nephropathy. Part II: Clinical, diagnostic and therapeutical aspects |
| Q40107790 | Urine liver fatty acid binding protein and chronic kidney disease progression. |
Search more.